A blockbuster Amgen antibody that treats bone conditions is set to face its first biosimilar competition. The FDA on Tuesday approved two Sandoz drugs as interchangeable with and approved for all uses ...

Cantor analysts cited early data suggesting bone safety risk Amgen confident in drug's profile, plans to release mid-stage study data later this year Amgen shares partially recover after a 7% decline ...

Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.

The agreement clears the way for launching denosumab biosimilars Jubbonti and Wyost on May 31, 2025, or earlier. Patent infringement proceedings were initially filed by Amgen in the U.S. Federal ...

LOS ANGELES, May 28 (Reuters) - Amgen Inc said on Wednesday its experimental osteoporosis drug denosumab achieved greater bone density than Merck & Co Inc's Fosamax, but some analysts expressed ...